Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Deferoxamine

🥰Excellent
Catalog No. T124358Cas No. 70-51-9
Alias Desferrioxamine B, Deferoxamine B

Deferoxamine (Desferrioxamine B) is an iron chelator. Deferoxamine can be used to reduce the accumulation and deposition of iron in tissues. Deferoxamine can improve neurological dysfunction by inhibiting ferroptosis and neuroinflammation after traumatic brain injury. It has antioxidant, anti-proliferation and anti-tumor activities, and can induce the production of HIF-1α, apoptosis and autophagy in cancer cells. It can be used to treat acute iron toxicity and COVID-19 related diseases.

Deferoxamine

Deferoxamine

🥰Excellent
Purity: 99.97%
Catalog No. T124358Alias Desferrioxamine B, Deferoxamine BCas No. 70-51-9
Deferoxamine (Desferrioxamine B) is an iron chelator. Deferoxamine can be used to reduce the accumulation and deposition of iron in tissues. Deferoxamine can improve neurological dysfunction by inhibiting ferroptosis and neuroinflammation after traumatic brain injury. It has antioxidant, anti-proliferation and anti-tumor activities, and can induce the production of HIF-1α, apoptosis and autophagy in cancer cells. It can be used to treat acute iron toxicity and COVID-19 related diseases.
Pack SizePriceAvailabilityQuantity
1 mg$61In Stock
5 mg$163In Stock
10 mg$256In Stock
25 mg$433In Stock
50 mg$638In Stock
100 mg$908In Stock
200 mg$1,230In Stock
Add to Cart
Add to Quotation
Bulk & Custom
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
View More

Batch Information

Select Batch
Purity:99.97%
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
Deferoxamine (Desferrioxamine B) is an iron chelator. Deferoxamine can be used to reduce the accumulation and deposition of iron in tissues. Deferoxamine can improve neurological dysfunction by inhibiting ferroptosis and neuroinflammation after traumatic brain injury. It has antioxidant, anti-proliferation and anti-tumor activities, and can induce the production of HIF-1α, apoptosis and autophagy in cancer cells. It can be used to treat acute iron toxicity and COVID-19 related diseases.
Targets&IC50
A2780 cells:3.5 μM, HCT-116 cells:> 200 μM, A549 cells:7.5 μM, DMS-53 cells:10 μM
In vitro
METHODS: MEF cells were treated with Deferoxamine (1 mM) for 16 hours or 4 weeks, and the intracellular ROS level was detected.
RESULTS: Deferoxamine reduces the ROS level in MEF cells. [1]
METHODS: Human hepatoma cell line HepG was treated with Deferoxamine mesylate (100 μM) for 24 hours, and the proteins of InsR and p-Akt/total Akt/PKB were detected by wb.
RESULTS: Deferoxamine enhances the expression and activity of InsR and induces an increase in p-Akt/total Akt/PKB levels. [2]
METHODS: Tumor-associated MSCs and bone marrow MSCs were treated with Deferoxamine (5, 10, 25, 50, 100 μM) for 7 or 9 days to detect cell proliferation.
RESULTS: Deferoxamine inhibits the proliferation of tumor-associated MSCs and bone marrow MSCs. [3]
METHODS: Mesenchymal stem cells were treated with Deferoxamine (5, 10, 25, 50, 100 μM) for 7 days, and apoptosis was detected.
RESULTS: Deferoxamine induces apoptosis of mesenchymal stem cells. [3]
METHODS: Mesenchymal stem cells were treated with Deferoxamine (10 μM) for 3 days, and the expression of adhesion proteins in mesenchymal stem cells was detected by wb.
RESULTS: Deferoxamine affects the expression of adhesion proteins in mesenchymal stem cells. [3]
METHODS: SH-SY5Y cells were treated with Deferoxamine (100 μM) for 24 h, and the level of HIF-1α was detected by wb.
RESULTS: Deferoxamine induces autophagy mediated by HIF-1α levels in SH-SY5Y cells. [4]
In vivo
METHODS: To study the role of Deferoxamine in wound healing in diabetes and the elderly, Deferoxamine was used to treat db/db mice (6.57 μg/ mouse; Drip infusion Once a day for 21 consecutive days.
RESULTS: Deferoxamine can promote wound healing and increase new angiogenesis in elderly or diabetic mice. [1]
METHODS: To study the effects of Deferoxamine on glucose uptake and insulin signaling, Deferoxamine was used to treat Sprague-Dawley rats (200 mg/kg; Intraperitoneal injection Once a day for two consecutive weeks.
RESULTS: Deferoxamine can stabilize HIF-1α and increase glucose uptake, enhance the expression of InsR in the liver and signal transduction in vivo. [2]
SynonymsDesferrioxamine B, Deferoxamine B
Chemical Properties
Molecular Weight560.68
FormulaC25H48N6O8
Cas No.70-51-9
SmilesO=C(NCCCCCN(O)C(=O)C)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN
Storage & Solubility Information
Storagestore at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 10 mg/mL (17.84 mM), Sonication is recommended.
H2O: 7.14 mg/mL (12.73 mM), Sonication is recommended.
Solution Preparation Table
H2O/DMSO
1mg5mg10mg50mg
1 mM1.7835 mL8.9177 mL17.8355 mL89.1774 mL
5 mM0.3567 mL1.7835 mL3.5671 mL17.8355 mL
10 mM0.1784 mL0.8918 mL1.7835 mL8.9177 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% Saline/PBS/ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Sci Citations

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Deferoxamine | purchase Deferoxamine | Deferoxamine cost | order Deferoxamine | Deferoxamine chemical structure | Deferoxamine in vivo | Deferoxamine in vitro | Deferoxamine formula | Deferoxamine molecular weight